CN118955500A - 4-(咪唑并[1,2-a]吡啶-3-基)-嘧啶衍生物 - Google Patents
4-(咪唑并[1,2-a]吡啶-3-基)-嘧啶衍生物 Download PDFInfo
- Publication number
- CN118955500A CN118955500A CN202411014632.3A CN202411014632A CN118955500A CN 118955500 A CN118955500 A CN 118955500A CN 202411014632 A CN202411014632 A CN 202411014632A CN 118955500 A CN118955500 A CN 118955500A
- Authority
- CN
- China
- Prior art keywords
- methyl
- pyridin
- pyrimidin
- amine
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19188031.9 | 2019-07-24 | ||
| EP19188031 | 2019-07-24 | ||
| PCT/EP2020/070616 WO2021013864A1 (en) | 2019-07-24 | 2020-07-22 | 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives |
| CN202080052946.6A CN114174293B (zh) | 2019-07-24 | 2020-07-22 | 4-(咪唑并[1,2-a]吡啶-3-基)-嘧啶衍生物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080052946.6A Division CN114174293B (zh) | 2019-07-24 | 2020-07-22 | 4-(咪唑并[1,2-a]吡啶-3-基)-嘧啶衍生物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118955500A true CN118955500A (zh) | 2024-11-15 |
Family
ID=67438678
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411014632.3A Pending CN118955500A (zh) | 2019-07-24 | 2020-07-22 | 4-(咪唑并[1,2-a]吡啶-3-基)-嘧啶衍生物 |
| CN202080052946.6A Active CN114174293B (zh) | 2019-07-24 | 2020-07-22 | 4-(咪唑并[1,2-a]吡啶-3-基)-嘧啶衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080052946.6A Active CN114174293B (zh) | 2019-07-24 | 2020-07-22 | 4-(咪唑并[1,2-a]吡啶-3-基)-嘧啶衍生物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220267320A1 (https=) |
| EP (1) | EP4003992A1 (https=) |
| JP (3) | JP7601852B2 (https=) |
| KR (2) | KR20250174707A (https=) |
| CN (2) | CN118955500A (https=) |
| AR (1) | AR119461A1 (https=) |
| AU (2) | AU2020318710B2 (https=) |
| BR (1) | BR112022001158A2 (https=) |
| CA (1) | CA3148227A1 (https=) |
| IL (1) | IL289953B2 (https=) |
| MX (1) | MX2022000794A (https=) |
| TW (1) | TWI868186B (https=) |
| WO (1) | WO2021013864A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240124450A1 (en) | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| CN120379972A (zh) * | 2022-12-20 | 2025-07-25 | 深圳湾实验室 | 一种靶向usp1的小分子抑制剂及其应用 |
| WO2025248485A1 (en) | 2024-05-31 | 2025-12-04 | Idrx, Inc. | Pharmaceutical compositions and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| US8124764B2 (en) * | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
| EP2430013B1 (en) * | 2009-05-13 | 2014-10-15 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| EA034866B1 (ru) | 2013-08-30 | 2020-03-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Замещенные пиримидиновые ингибиторы bmi-1 |
-
2020
- 2020-07-22 BR BR112022001158A patent/BR112022001158A2/pt unknown
- 2020-07-22 IL IL289953A patent/IL289953B2/en unknown
- 2020-07-22 CA CA3148227A patent/CA3148227A1/en active Pending
- 2020-07-22 AU AU2020318710A patent/AU2020318710B2/en active Active
- 2020-07-22 WO PCT/EP2020/070616 patent/WO2021013864A1/en not_active Ceased
- 2020-07-22 KR KR1020257039581A patent/KR20250174707A/ko active Pending
- 2020-07-22 EP EP20750187.5A patent/EP4003992A1/en active Pending
- 2020-07-22 CN CN202411014632.3A patent/CN118955500A/zh active Pending
- 2020-07-22 US US17/597,729 patent/US20220267320A1/en active Pending
- 2020-07-22 MX MX2022000794A patent/MX2022000794A/es unknown
- 2020-07-22 JP JP2022504198A patent/JP7601852B2/ja active Active
- 2020-07-22 CN CN202080052946.6A patent/CN114174293B/zh active Active
- 2020-07-22 KR KR1020227005802A patent/KR102894509B1/ko active Active
- 2020-07-23 TW TW109124903A patent/TWI868186B/zh active
- 2020-07-23 AR ARP200102060A patent/AR119461A1/es unknown
-
2024
- 2024-12-05 JP JP2024212157A patent/JP7730407B2/ja active Active
-
2025
- 2025-08-15 JP JP2025135307A patent/JP2025186243A/ja active Pending
- 2025-10-30 US US19/373,991 patent/US20260109697A1/en active Pending
-
2026
- 2026-01-23 AU AU2026200481A patent/AU2026200481A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL289953B1 (en) | 2024-11-01 |
| AU2020318710B2 (en) | 2025-11-20 |
| KR20220041133A (ko) | 2022-03-31 |
| BR112022001158A2 (pt) | 2022-05-17 |
| EP4003992A1 (en) | 2022-06-01 |
| JP2025186243A (ja) | 2025-12-23 |
| KR102894509B1 (ko) | 2025-12-02 |
| US20260109697A1 (en) | 2026-04-23 |
| IL289953B2 (en) | 2025-03-01 |
| WO2021013864A1 (en) | 2021-01-28 |
| TWI868186B (zh) | 2025-01-01 |
| JP7730407B2 (ja) | 2025-08-27 |
| KR20250174707A (ko) | 2025-12-12 |
| AU2026200481A1 (en) | 2026-02-12 |
| JP7601852B2 (ja) | 2024-12-17 |
| TW202118762A (zh) | 2021-05-16 |
| MX2022000794A (es) | 2022-02-16 |
| US20220267320A1 (en) | 2022-08-25 |
| AR119461A1 (es) | 2021-12-22 |
| IL289953A (en) | 2022-03-01 |
| CA3148227A1 (en) | 2021-01-28 |
| AU2020318710A1 (en) | 2022-03-10 |
| CN114174293B (zh) | 2024-08-06 |
| JP2022542072A (ja) | 2022-09-29 |
| CN114174293A (zh) | 2022-03-11 |
| JP2025060626A (ja) | 2025-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL323371A (en) | Broadly neutralizing antibodies against the AIDS virus | |
| JP7730407B2 (ja) | ４－（イミダゾ［１，２－ａ］ピリジン－３－イル）－ピリミジン誘導体 | |
| JP7744540B2 (ja) | がんなどの疾患の処置のためのインダゾリル－イソオキサゾール誘導体 | |
| RU2822388C2 (ru) | 4-(ИМИДАЗО[1,2-а]ПИРИДИН-3-ИЛ)-ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ | |
| RU2836662C2 (ru) | Индазолилизоксазольные производные для лечения заболеваний, таких как злокачественное новообразование | |
| HK40122817A (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | |
| HK40065185A (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |